Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Back
Share this video  

iwMyeloma 2017 | Liquid biopsies for multiple myeloma: the attractions and limits

Jens Lohr • 18 Oct 2017
iwMyeloma 2017
Multiple Myeloma

Technological advances have allowed for whole genome, exome and transcriptome sequencing of circulating multiple myeloma (MM) cells and cell-free tumor DNA. In this video, Jens Lohr, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA, highlights the advantages of this. Dr Lohr also addresses the limitation of liquid biopsies, including patient selection and standardization. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.

More from Jens Lohr

6:28
MRD detection in myeloma: single cell RNAseq, protein-based & VDJ sequencing
Angela Dispenzieri et al. • 10 Sep 2018
10:35
Is MRD testing ready for prime time in myeloma?
Angela Dispenzieri et al. • 10 Sep 2018
0:49
The biases of using bone marrow biopsies for multiple myeloma
Jens Lohr • 18 Oct 2017

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals